TY - JOUR
T1 - International Dermatology Outcome Measures (IDEOM)
T2 - Report from the 2020 Annual Meeting
AU - Kohn, Alison H.
AU - Alavi, Afsaneh
AU - Armstrong, April W.
AU - Babalola, Folawiyo
AU - Garg, Amit
AU - Gottlieb, Alice B.
AU - Grilli, Lesley
AU - Jemec, Gregor Borut Ernst
AU - Latella, John
AU - Marcus, Kendall
AU - Merola, Joseph F.
AU - Ortega-Loayza, Alex G.
AU - Siegel, Daniel M.
AU - Strand, Vibeke
AU - Tan, Jerry K.L.
AU - Perez-Chada, Lourdes M.
N1 - Publisher Copyright:
© 2021 The Author(s). Published by S. Karger AG, Basel.
PY - 2022/5/1
Y1 - 2022/5/1
N2 - Background: The International Dermatology Outcome Measures (IDEOM) initiative is a non-profit organization that aims to develop evidence-based outcome measurements to evaluate the impact of treatments for patients with dermatological disease. IDEOM includes all key stakeholders in dermatology (patient, physician, industry, insurer, and government) during the process of developing such outcome measurements. Summary: Here, we provide an update of IDEOM activities that were presented at the 2020 IDEOM Virtual Annual Meeting (October 23-24, 2020). During the meeting, multiple IDEOM workgroups (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) shared their progress to date, as well as future directions in developing and validating Patient-Reported Outcome Measures. Updates on demonstrating efficacy in clinicals trials by the US Food and Drug Administration are also summarized. Key Messages: In this report, we summarize the work presented by each IDEOM workgroup (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) at the 2020 IDEOM Virtual Annual Meeting.
AB - Background: The International Dermatology Outcome Measures (IDEOM) initiative is a non-profit organization that aims to develop evidence-based outcome measurements to evaluate the impact of treatments for patients with dermatological disease. IDEOM includes all key stakeholders in dermatology (patient, physician, industry, insurer, and government) during the process of developing such outcome measurements. Summary: Here, we provide an update of IDEOM activities that were presented at the 2020 IDEOM Virtual Annual Meeting (October 23-24, 2020). During the meeting, multiple IDEOM workgroups (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) shared their progress to date, as well as future directions in developing and validating Patient-Reported Outcome Measures. Updates on demonstrating efficacy in clinicals trials by the US Food and Drug Administration are also summarized. Key Messages: In this report, we summarize the work presented by each IDEOM workgroup (psoriasis, psoriatic arthritis, hidradenitis suppurativa, acne, pyoderma gangrenosum, and actinic keratosis) at the 2020 IDEOM Virtual Annual Meeting.
KW - Acne
KW - Actinic keratosis
KW - Hidradenitis suppurativa
KW - IDEOM
KW - Patient-Reported Outcome Measures
KW - Psoriasis
KW - Psoriatic arthritis
KW - Pyoderma gangrenosum
UR - https://www.scopus.com/pages/publications/85115977492
U2 - 10.1159/000518966
DO - 10.1159/000518966
M3 - Review
C2 - 34537770
AN - SCOPUS:85115977492
SN - 1018-8665
VL - 238
SP - 430
EP - 437
JO - Dermatology
JF - Dermatology
IS - 3
ER -